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Abstract
Background: Persons with certain neurological conditions have higher mortality rates than the population without
neurological conditions, but the risk factors for increased mortality within diagnostic groups are less well understood. The
interRAI CHESS scale has been shown to be a strong predictor of mortality in the overall population of persons receiving
health care in community and institutional settings. This study examines the performance of CHESS as a predictor of
mortality among persons with 11 different neurological conditions.
Methods: Survival analyses were done with interRAI assessments linked to mortality data among persons in home care
(n = 359,940), complex continuing care hospitals/units (n = 88,721), and nursing homes (n = 185,309) in seven Canadian
provinces/territories.
Results: CHESS was a significant predictor of mortality in all 3 care settings for the 11 neurological diagnostic groups
considered after adjusting for age and sex. The distribution of CHESS scores varied between diagnostic groups and within
diagnostic groups in different care settings.
Conclusions: CHESS is a valid predictor of mortality in neurological populations in community and institutional care. It may
prove useful for several clinical, administrative, policy-development, evaluation and research purposes. Because it is
routinely gathered as part of normal clinical practice in jurisdictions (like Canada) that have implemented interRAI
assessment instruments, CHESS can be derived without additional need for data collection.
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Introduction
The World Health Organization estimates that neurological
conditions account for about 12% of global deaths and about 14%
of years of healthy life lost to death [1]. For many developed
nations, neurological deaths have gained prominence in relation to
total mortality in the last three decades [2]. Certain neurological
conditions (e.g., multiple sclerosis, stroke, TIA, parkinsonism) are
associated with higher risks of mortality rates compared with
persons without those conditions [3,4]; however, the risk factors
for increased mortality within diagnostic groups are less well
understood. Algorithms to predict mortality have been developed
specifically for persons with ALS [5,6], Parkinsons disease [7] and
Traumatic Brain Injury [8] using a variety of functional, clinical,
and laboratory based indicators. Although some disease-specific
methods appear to perform well at predicting survival times, these
algorithms are often not applicable across neurological conditions
or to non-neurological populations. In addition, the indicators
employed in these algorithms are often not readily available in
existing medical records.
The Changes in Health, End-stage disease, and Signs and
Symptoms (CHESS) scale has been shown to predict mortality,
health service use, and caregiver distress in the overall populations
of persons receiving care in home care, post-acute, nursing home
and palliative care settings [9–14]. CHESS is a summary measure
based on a count of decline in Activities of Daily Living (ADL);
decline in cognition; symptoms such as weight loss, shortness of
breath, and edema; and clinician ratings of a prognosis of less than
six months. Although counts of deficits [15–17] can be useful
indicators of frailty in older populations, CHESS has been shown
to be a stronger predictor of time to adverse outcomes in home
care clients than the Frailty Index [13]. CHESS scores are
standardized algorithms obtained from items embedded in the
interRAI assessment instruments, which have been adopted across
the continuum of care in several countries including Canada [18–
19]. As a result, persons of different ages receiving care in different
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service settings can be compared directly with equivalent
measures.
While CHESS has been shown to be a good predictor of a
variety of adverse outcomes in the overall population of persons
receiving non-acute care, it is not clear whether it would function
equally well among diagnostic subgroups. Previous research
showed that CHESS is a more effective predictor of mortality in
nursing home residents with heart failure compared with the New
York Heart Association (NYHA) classification [20], but it has not
been evaluated specifically for persons with neurological condi-
tions. Given that these data are readily available in countries
where interRAI instruments have been adopted as standardized
assessments [19,21], it would be useful to know how the scale
performs in specialized subpopulations who would be assessed
with the interRAI instrument as part of routine clinical practice.
This research was undertaken as part of the National Population
Health Study of Neurological Conditions (NPHSNC), which
aimed to examine the scope, impact, risk factors and health service
use related to neurological conditions in Canada [22].
Materials and Methods
Ethics
Ethics clearance for this research was obtained through the
Office of Research Ethics at the University of Waterloo.
Sample
The samples considered in the present analyses include persons
in three care settings with 10 neurological conditions identified as
priorities for the NPHSNC (i.e., Alzheimer’s and related dementia,
Parkinson’s disease, Traumatic Brain Injury, Epilepsy, Multiple
Sclerosis, Cerebral Palsy, Amyotrophic Lateral Sclerosis, Spinal
Cord Injury, Muscular Dystrophy, Huntington’s Disease), stroke,
and other non-neurological conditions. Although stroke was not
identified as a priority condition by the funders of NPHSNC, it
was retained for the present analyses given its importance as a
neurological condition. For some analyses, the 10 priority
conditions and stroke are combined as a single neurological
conditions group; however, the conditions are also examined
separately because it is unlikely that all neurological conditions
have the same relationship to mortality.
The samples examined in the present study included Canadian
long stay home care (HC) clients in Ontario, Winnipeg Regional
Health Authority, and the Yukon Territory (n = 359,940). This
included 140,765 persons with one or more of the above-
mentioned 11 neurological conditions among those home care
clients. In addition, data were available for 88,721 Ontario and
Winnipeg Regional Health Authority complex continuing care
hospital (CCC) patients and 185,309 long term care home (LTC)
residents in Ontario, Winnipeg Regional Health Authority,
Saskatchewan, Yukon Territory, British Columbia, Nova Scotia,
and Newfoundland (50,277 and 146,165 had one or more of the
neurological conditions of interest in those settings, respectively).
All persons assessed as part of normal clinical practice with
either the Resident Assessment Instrument (RAI 2.0) in CCC or
LTC between 2003–2010 or the RAI-Home Care (RAI-HC) in
HC settings between 2007-2011 were eligible for inclusion in the
study sample. For home care where reassessments are normally
conducted between six and 12 months, the last assessment was
used. For those in CCC and LTC where 3 month reassessment is
done, the observation closest to July 1 in the last year they were
assessed was used to construct an observational cohort.
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Data source
The two primary data sources for the study were the Canadian
Institute for Health Information’s (CIHI) Home Care Reporting
System and Continuing Care Reporting System, which house the
RAI 2.0 and RAI-HC data on a national basis in Canada. The
eight provinces/territories that have mandated implementation of
one or more interRAI instruments submit their data to CIHI for
national statistical reporting. CIHI in turned linked the assessment
data to the hospital Discharge Abstract Database (DAD), National
Ambulatory Care Reporting System (NACRS) in order to permit
longitudinal follow-up. Mortality was tracked over a six month
period following the baseline assessment using these various
information sources, and surviving cases were censored at June 30,
2011.
The data used in the present analyses were provided to the
research team by CIHI as part of a pre-existing data sharing
agreement between interRAI and CIHI. The data are not publicly
available and cannot be transmitted to third parties due to legal
terms specified in this license agreement; however, other
researchers may apply to CIHI for access to the data through
another data sharing mechanism available to the general research
community in Canada. The data are hosted on a secure server at
the University of Waterloo, which meets CIHI’s standards for
privacy protection. All data were de-identified by CIHI prior to
transmission to the University of Waterloo.
The RAI 2.0 and RAI-HC assessments each comprise over 350
sociodemographic, administrative, clinical and diagnostic items at
the individual level. In addition to the 11 neurological conditions
of interest here, these assessments gather information related to a
broad range of functional and clinical measures including the
CHESS scale. Evidence about the reliability and validity of the
interRAI family of assessment instruments has been reported
elsewhere [23–27], including reports on the validity of diagnostic
data in these assessments [28–29].
Statistical analysis
The first analytic steps focused on the description of the study
samples in each of the three care settings of interest by diagnosis
with the aim of understanding differences in the distributions of
underlying risk factors for mortality between the diagnostic groups
(e.g., age, sex). The diagnostic groups were coded as a series of
binary variables that were not mutually exclusive (e.g., persons
with traumatic brain injury and epilepsy were coded as having the
diagnosis ‘‘present’’ for both binary variables); however, the group
‘‘None of these 11 conditions’’ had none of the 11 neurological
conditions of interest present. In addition, the relationships
between diagnosis and clinical characteristics like cognitive
impairment, physical disability, depression and CHESS scores
were also examined.
Proportional hazards models were used to examine mortality
within each of the neurological subgroups and among persons with
none of the neurological conditions of interest. In addition, the
survival rates for all persons in each of the HC, LTC and CCC
settings were examined by neurological condition after controlling
for CHESS, age, and sex. It was not the aim of the present study to
develop definitive, comprehensive models of all risk factors for
mortality within each neurological condition, but rather to explore
the utility of the CHESS scale for persons with neurological
conditions. All diagnoses were included in the multivariate
analyses as dummy variables, which would permit persons with
multiple neurological diagnoses to be included in the model and
would permit estimates of the independent explanatory power of
individual diagnoses after adjusting for comorbid conditions.
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Table 3. Age- and sex-adjusted hazard ratios for mortality by CHESS score, setting and diagnosis in five Canadian provinces/
territories.
Setting and Diagnosis Age-Sex Adjusted Hazard Ratio (95% CI) by CHESS Score (Ref = 0)
n 1 2 3 4 5
Home care
All HC clients 359,940 1.51 2.22 3.87 6.57 18.98
(1.46–1.55) (2.15–2.29) (3.75–4.00) (6.31–6.83) (17.57–20.51)
Amyotrophic Lateral Sclerosis 1,264 2.05 2.86 3.53 6.69 13.38
(1.23–3.39) (1.74–4.69) (2.10–5.94) (3.61–12.43) (4.49–39.88)
Cerebral Palsy 1,413 1.85 2.13 4.02 19.11 ——1
(0.99–3.47) (1.01–4.48) (1.37–11.86) (5.42–67.40)
Alzheimer’s & Related Dementias 106,603 1.36 1.61 2.65 4.24 13.96
(1.28–1.44) (1.52–1.70) (2.50–2.82) (3.95–4.55) (11.82–16.47)
Epilepsy 9,716 1.28 1.83 2.85 4.37 28.63
(1.03–1.59) (1.49–2.25) (2.27–3.57) (3.24–5.89) (17.70–46.30)
Huntington’s Disease 304 1.14 2.16 3.87 3.49 ——
(0.25–5.18) (0.53–8.72) (0.64–23.28) (0.32–38.33)
Muscular Dystrophy 4,852 0.94 1.42 3.84 5.84 14.88
(0.69–1.28) (1.04–1.96) (2.74–5.39) (3.35–10.18) (5.34–41.49)
Multiple Sclerosis 696 1.39 2.40 2.61 —— ——
(0.76–2.53) (1.27–4.54) (1.18–5.80)
Parkinson’s Disease 17,915 1.17 1.51 2.32 3.54 12.37
(1.03–1.34) (1.32–1.72) (2.01–2.69) (2.94–4.27) (7.70–19.88)
Spinal Cord Injury 794 1.36 1.10 3.74 5.03 ——
(0.69–2.70) (0.45–2.73) (1.61–8.70) (1.09–23.23)
Stroke 88,549 1.33 1.71 2.62 4.00 13.54(
(1.26–1.41) (1.62–1.80) (2.47–2.78) (3.71–4.32) 11.48–15.97)
Traumatic Brain Injury 13,722 1.25 1.60 2.32 3.73 16.65
(1.08–1.45) (1.38–1.85) (1.98–2.73) (3.04–4.58) (9.89–28.02)
None of these 11 conditions 219,175 1.60 2.69 4.76 9.11 20.94
(1.54–1.66) (2.59–2.80) (4.57–4.95) (8.67–9.58) (19.11–22.94)
Complex Continuing Care Hospitals/Units
All CCC patients 88,721 1.58 2.52 4.71 9.14 21.07
(1.49–1.67) (2.39–2.66) (4.47–4.96) (8.68–9.63) (19.98–22.21)
Amyotrophic Lateral Sclerosis 654 1.18 1.87 2.52 5.09 8.73
(0.80–1.74) (1.30–2.68) (1.73–3.67) (3.39–7.63) (5.33–14.29)
Cerebral Palsy 531 1.08 1.61 3.65 6.26 18.33
(0.64–1.82) (0.97–2.66) (2.01–6.64) (3.14–12.47) (8.67–38.76)
Alzheimer’s & Related Dementias 26,336 1.57 2.03 3.25 5.74 16.64
(1.43–1.73) (1.85–2.21) (2.98–3.54) (5.26–6.26) (15.19–18.22)
Epilepsy 5,880 1.80 2.37 4.47 8.86 17.09
(1.50–2.16) (1.99–2.84) (3.76–5.32) (7.47–10.51) (14.39–20.29)
Huntington’s Disease 184 1.33 1.66 0.87 1.30 32.46
(0.72–2.46) (0.84–3.28) (0.34–2.17) (0.48–3.51) (11.88–88.72)
Muscular Dystrophy 1,213 1.20 2.08 2.98 6.92 20.10
(0.88–1.65) (1.49–2.90) (2.07–4.29) (4.89–9.80) (13.11–30.81)
Multiple Sclerosis 175 1.53 5.58 6.26 9.05 8.40
(0.40–5.87) (1.82–17.11) (1.77–22.11) (1.95–42.06) (0.90–78.18)
Parkinson’s Disease 4,622 1.24 1.98 2.98 5.46 21.43
(0.99–1.55) (1.62–2.43) (2.42–3.65) (4.44–6.70) (17.08–26.88)
Spinal Cord Injury 2875 1.56 2.44 4.75 10.02 20.79
(1.27–1.91) (2.00–2.99) (3.86–5.85) (8.12–12.35) (16.67–25.94)
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In addition, logistic regression models using the same indepen-
dent variables employed in the survival models were used to model
6-month mortality as a binary dependent variable. The c statistics
obtained from these models were used to provide information on
the explanatory power of the models and their components.
The 6-month follow-up period for mortality was chosen to
reflect the recommended interval between assessments in home
care. In the other two settings, a shorter reassessment cycle (three
months) is used. Therefore, half a year is the longest recommended
time period without a follow-up assessment that would provide
new information to inform clinical action. In other words, the time
frame used in the survival models reflects the period for which
assessments are intended to inform clinical responses to the
person’s needs before being reassessed.
In addition to the hazard ratios provided by the survival models,
estimates of the death rate per 1,000 person years were derived to
illustrate the magnitude of mortality across settings and between
diagnostic groups.
The analyses were done for the three care settings separately,
rather than as a pooled sample, because the individual sectors
would be particularly interested in the applicability of the CHESS
within their own setting. In addition, the mortality rates differ
substantially between settings for all cases combined and for
individual diagnostic groups.
Results
Table 1 provides a summary of the demographic and clinical
characteristics of the samples of persons with neurological
Table 3. Cont.
Setting and Diagnosis Age-Sex Adjusted Hazard Ratio (95% CI) by CHESS Score (Ref = 0)
n 1 2 3 4 5
Stroke 26,874 1.46 2.08 3.63 6.88 20.48
(1.33–1.61) (1.90–2.28) (3.32–3.97) (6.29–7.51) (18.67–22.48)
Traumatic Brain Injury 3,974 1.60 2.05 3.92 6.54 23.19
(1.25–2.04) (1.62–2.60) (3.10–4.95) (5.15–8.30) (17.90–30.04)
None of these 11 conditions 38,444 1.57 2.99 5.87 11.42 21.74
(1.41–1.75) (2.71–3.30) (5.32–6.46) (10.38–12.56) (19.75–23.94)
Nursing Homes
All NH residents 185,309 1.57 2.43 3.92 6.69 22.76
(1.53–1.60) (2.37–2.49) (3.81–4.04) (6.46–6.93) (21.53–24.06)
Amyotrophic Lateral Sclerosis 652 1.33 2.01 2.50 7.81 ——
(0.91–1.93) (1.37–2.94) (1.42–4.40) (4.28–14.24)
Cerebral Palsy 2,359 1.41 1.82 2.65 3.50 7.96
(1.19–1.69) (1.51–2.20) (2.08–3.38) (2.59–4.72) (4.72–13.42)
Alzheimer’s & Related Dementias 118,429 1.53 2.29 3.66 6.22 24.08
(1.49–1.57) (2.22–2.36) (3.52–3.80) (5.94–6.51) (22.39–25.89)
Epilepsy 11,407 1.65 2.41 3.59 6.42 20.29
(1.51–1.81) (2.17–2.67) (3.14–4.10) (5.48–7.52) (16.12–25.54)
Huntington’s Disease 469 2.73 3.01 7.13 8.23 37.95
(1.69–4.40) (1.67–5.43) (3.37–15.09) (3.12–21.67) (8.44–170.70)
Muscular Dystrophy 3,588 1.50 2.11 3.86 5.34 17.80
(1.27–1.78) (1.76–2.52) (3.12–4.76) (4.12–6.93) (9.11–34.78)
Multiple Sclerosis 185 0.98 1.98 11.63 14.70 ——
(0.49–1.97) (0.89–4.41) (3.74–36.21) (2.95–73.18)
Parkinson’s Disease 13,748 1.49 2.41 4.02 6.93 26.16
(1.37–1.62) (2.20–2.63) (3.58–4.50) (6.01–7.99) (21.34–32.06)
Spinal Cord Injury 1421 1.44 1.71 5.48 6.16 14.15
(1.12–1.85) (1.26–2.31) (3.82–7.86) (3.53–10.74) (6.19–32.37)
Stroke 52,156 1.51 2.34 4.02 7.07 27.74
(1.45–1.58) (2.23–2.45) (3.78–4.27) (6.59–7.58) (25.06–30.72)
Traumatic Brain Injury 8,500 1.71 2.60 4.14 7.20 34.96
(1.52–1.91) (2.29–2.94) (3.54–4.83) (5.97–8.68) (26.46–46.19)
None of these 11 conditions 39,144 1.62 2.60 4.02 6.77 18.64
(1.55–1.70) (2.48–2.73) (3.79–4.26) (6.33–7.25) (16.73–20.75)
1Cells with double dashes do not have hazard ratios due to small cell sizes.
doi:10.1371/journal.pone.0099066.t003
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Figure 1. Survival curves for persons with any of 11 neurological conditions by CHESS score in hospital based continuing care (1a),
nursing homes (1b), or home care (1c).
doi:10.1371/journal.pone.0099066.g001
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conditions and those with none of the 11 conditions of interest in
all three care settings. Substantial differences in the age and sex
distributions by diagnosis are evident within settings; however,
these differences also occur within diagnostic groups in different
care settings. For example persons with cerebral palsy and
muscular dystrophy tend to be youngest and those with
Alzheimer’s and related dementias are the oldest in each care
setting. However, for each diagnostic group, those in HC and
CCC tend to be younger than in LTC. In addition, persons with
multiple sclerosis have the highest percentage of females in all
three settings.
There are also substantial differences in cognitive impairment,
functional status, depressive symptoms and CHESS scores across
settings and between diagnostic groups (see Tables 1 and 2).
Compared with persons without any of the 11 conditions of
interest, the neurological subgroups have higher rates of moderate
or worse cognitive and ADL impairment. Less pronounced
differences are evident for depressive symptoms. However, for
all three of these clinical issues the rates are lower in HC compared
with facility based settings. On the other hand, the percentage with
CHESS scores of two or more are lowest in LTC homes and
highest in CCC hospitals/units, and these trends are evident
within diagnostic groups across settings (Table 2).
These clinical and demographic differences indicate that there is
substantial heterogeneity within and between persons with
different types of neurological conditions across the continuum
of care that would not be taken into account if one considered
diagnosis alone. Table 3 provides the age and sex-adjusted hazard
ratios and 95% confidence limits for the CHESS scale for each
neurological condition in the three care settings. For almost all
conditions in HC, LTC, and CCC there were consistent
increments in the hazard ratios for six month mortality by
Table 4. Unadjusted and adjusted hazard ratios controlling for age, sex and CHESS score by diagnosis and care setting in five
Canadian provinces.
Independent Variable Home Care (n =359,940) CCC hospitals/units (n =88,721) Nursing homes (n=185,309)
Unadjusted HR Adjusted HR Unadjusted HR Adjusted HR Unadjusted HR Adjusted HR
Age group (ref,65)
65–74 1.38 (1.33–1.43) 1.12 (1.07–1.16) 1.51 (1.42–1.62)
75–84 1.48 (1.43–1.53) 1.07 (1.04–1.11) 2.05 (1.93–2.17)
85+ 1.76 (1.70–1.82) 1.12 (1.08–1.16) 2.66 (2.51–2.81)
Female 0.65 (0.64–0.66) 0.86 (0.85–0.88) 0.74 (0.73–0.76)
CHESS score (ref =0)
1 1.51 (1.46–1.55) 1.54 (1.45–1.63) 1.57 (1.53–1.60)
2 2.28 (2.21–2.35) 2.46 (2.33–2.59) 2.42 (2.36–2.48)
3 3.93 (3.81–4.06) 4.53 (4.30–4.78) 3.90 (3.79–4.02)
4 6.90 (6.64–7.18) 8.72 (8.27–9.18) 6.70 (6.47–6.94)
5 18.80 (17.40–20.32) 19.32 (18.32–20.38) 22.40 (21.18–23.68)
Amyotrophic Lateral Sclerosis 2.14 (1.92–2.39) 1.97 (1.76–2.20) 0.98 (0.88–1.09) 1.19 (1.07–1.33) 1.00 (0.87–1.15) 1.12 (0.97–1.29)
Cerebral Palsy 0.35 (0.27–0.45) 0.59 (0.46–0.77) 0.43 (0.37–0.52) 0.78 (0.65–0.92) 1.23 (1.15–1.31) 1.35 (1.26–1.44)
Alzheimer’s & Related
Dementias
0.93 (0.91–0.95) 0.74 (0.72–0.75) 0.78 (0.76–0.80) 0.83 (0.81–0.85) 0.86 (0.85–0.88) 0.84 (0.82–0.85)
Epilepsy 0.70 (0.65–0.75) 0.78 (0.72–0.83) 0.81 (0.85–0.92) 1.01 (0.97–1.10) 0.88 (0.85–0.91) 1.05 (1.01–1.09)
Huntington’s Disease 0.45 (0.27–0.73) 0.63 (0.39–1.04) 0.66 (0.53–0.82) 0.93 (0.75–1.16) 0.68 (0.56–0.83) 1.15 (0.94–1.39)
Muscular Dystrophy 1.02 (0.82–1.26) 1.36 (1.09–1.70) 0.35 (0.25–0.48) 0.49 (0.36–0.69) 0.97 (0.74–1.27) 1.33 (1.01–1.75)
Multiple Sclerosis 0.46 (0.41–0.51) 0.66 (0.59–0.74) 0.56 (0.50–0.62) 0.87 (0.78–0.96) 0.91 (0.85–0.97) 1.09 (1.02–1.16)
Parkinson’s Disease 0.93 (0.90–0.97) 0.86 (0.82–0.90) 0.71 (0.67–0.74) 0.85 (0.80–0.89) 0.91 (0.88–0.94) 0.96 (0.93–0.99)
Spinal Cord Injury 0.51 (0.39-0.67) 0.68 (0.52–0.89) 0.76 (0.72–0.81) 1.13 (1.07–1.20) 0.92 (0.84–1.02) 1.18 (1.06–1.30)
Stroke 1.13 (1.11–1.15) 1.05 (1.03–1.07) 0.64 (0.62–0.65) 0.80 (0.78–0.82) 0.85 (0.83–0.87) 0.89 (0.87–0.91)
Traumatic Brain Injury 0.95 (0.91–1.00) 1.00 (0.95–1.46) 0.50 (0.47–0.53) 0.69 (0.64–0.73) 0.80 (0.77–0.84) 0.93 (0.89–0.97)
doi:10.1371/journal.pone.0099066.t004
Table 5. C statistics (95% CL) for multiple logistic regression models including age, sex, diagnoses and CHESS score, by care
setting in five Canadian provinces/territories.
Model Home Care Nursing Homes Complex Continuing Care Hospitals/Units
Adjusted for age, sex, diagnoses 0.622 (0.619, 0.625) 0.608 (0.605, 0.611) 0.649 (0.645, 0653)
Adjusted for age, sex, diagnoses, CHESS score 0.752 (0.749, 0.755) 0.713 (0.710, 0.716) 0.829 (0.826, 0.832)
doi:10.1371/journal.pone.0099066.t005
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CHESS score within the diagnostic group. In a few cases, small
cell sizes resulted in confidence intervals overlapping with 1.00.
Only Huntington’s disease failed to show a strong association
between CHESS scores and survival in HC and CCC; however,
higher CHESS scores were strongly associated with higher hazard
ratios for mortality among residents with Huntington’s in LTC.
The magnitude of changes in hazard ratios for each increment
in the CHESS scale varied somewhat by diagnostic group. For
example, the increase in hazard ratios for persons with CP in LTC
Table 6. Deaths per 1,000 person-years by CHESS score, diagnosis and care setting in five Canadian provinces/territories.
Diagnosis CHESS Score Home Care Nursing Homes Complex Continuing Care Hospitals/Units
Rate (95% CL) Rate (95% CL) Rate (95% CL)
Alzheimer’s and Related Dementia 0 221 (209–232) 491 (481–501) 937 (848–1,030)
1 302 (290–315) 762 (745–778) 1,495 (1,383–1,614)
2 359 (346–372) 1,153 (1,124–1,183) 1,953 (1,829–2,083)
3 597 (570–624) 1,878 (1,807–1,951) 3,179 (2,983–3,387)
4 957 (897–1,020) 3,244 (3,069-3,430) 5,751 (5,388–6,141)
5 3,113 (2,483–3,910) 12,547 (11,054–14,409) 17,478 (16,145–19,007)
All 371 (363–378) 802 (793–812) 2,673 (2,596–2,752)
Multiple Sclerosis 0 135 (104–167) 448 (390–507) 869 (634–1,148)
1 126 (97–157) 722 (632–817) 1,050 (779–1,375)
2 201 (152–253) 1,116 (959–1,288) 1,882 (1,332–2,599)
3 545 (393–715) 2,187 (1,780–2,676) 2,947 (1,968–4,381)
4 904 (429–1,560) 3,105 (2,308–4,206) 6,703 (4,616–10,238)
5 2,910 (209–45,737) 10,084 (3,927–47,131) 22,400 (15,269–38,440)
All 181 (159–203) 774 (722–829) 1,648 (1,431–1,888)
Parkinson’s Disease 0 248 (219–277) 476 (446–506) 933 (737–1,157)
1 293 (266–320) 719 (673–767) 1,164 (954–1,402)
2 383 (350–417) 1,167 (1,078–1,261) 1,874 (1,598–2,186)
3 595 (528–665) 1,991 (1,764–2,243) 2,855 (2,429–3,345)
4 903 (743–1,081) 3,551 (2,979–4,252) 5,337 (4,509–6,338)
5 3,428 (1,665–7,371) 13,660 (9,612–21,919) 21,775 (17,841–27,517)
All 365 (347–382) 774 (747–802) 2,258 (2,097–2,430)
Stroke 0 259 (247–272) 457 (442–472) 787 (713–864)
1 351 (337–365) 703 (679–728) 1,189 (1,097–1,286)
2 458 (441–476) 1,111 (1,065–1,158) 1,721 (1,607–1,841)
3 707 (675–740) 1,959 (1,838-2,088) 3,100 (2,893–3,320)
4 1,097 (1,018–1,181) 3,519 (3,224–3,846) 6,044 (5,632–6,490)
5 3,572 (2,851–4,501) 13,762 (11,583–16,748) 19,003 (17,436–20,825)
All 427 (419–436) 753 (739-767) 2,305 (2,235–2,376)
Traumatic Brain Injury 0 227 (200–256) 388 (355–422) 601 (471–746)
1 316 (283–351) 694 (634–756) 980 (785–1,203)
2 417 (375–461) 1,077 (965–1,196) 1,303 (1,060–1,579)
3 619 (541-701) 1,743 (1,476–2,049) 2,526 (2,068–3,066)
4 1,039 (838–1,266) 3,041 (2,400–3,870) 4,346 (3,472–5,456)
5 4,224 (1,984–9,411) 14,425 (9,478–25,812) 16,374 (12,611–22,529)
All 373 (353–393) 680 (648–713) 1,580 (1,447–1,722)
None of Above 11 Conditions 0 170 (163–177) 598 (575–622) 872 (772–978)
1 286 (277–294) 991 (954–1029) 1376 (1269–1489)
2 503 (489–518) 1,597 (1,534–1,663) 2,605 (2,455–2,762)
3 933 (904–962) 2,531 (2,388–2,683) 5,225 (4,973–5,491)
4 1,885 (1,784–1,990) 4,309 (3,989–4,660) 10,492 (10,044–10,968)
5 4,097 (3,584–4,699) 10,798 (9,262–12,794) 21,546 (20,543–22,633)
All 403 (397–409) 1,112 (1,090–1,134) 4,718 (4,610–4,830)
doi:10.1371/journal.pone.0099066.t006
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homes was significant, but much less pronounced than for other
diagnostic groups in those settings. Also, the hazard ratios for
CHESS scores of 5 differed by diagnosis, but they were
consistently associated with dramatically higher hazard ratios
compared with the reference group of CHESS equal to 0. The
small cell sizes for some conditions (e.g., Muscular Dystrophy)
result in estimates with wide confidence intervals, but the general
trend of increased hazard ratios with higher CHESS scores is quite
consistent.
Figures 1a to 1c provide the survival curves for persons with any
of the 11 neurological conditions by CHESS score across the three
care settings. In each case, the CHESS score differentiated the
survival experience of persons with neurological conditions.
However, the differences in survival by CHESS were largest in
facility based settings and survival rates were generally the lowest
in CCC hospitals/units.
Table 4 provides the results for multivariate proportional
hazards models for six month survival by care setting using
diagnosis as a covariate rather than a stratification variable. In HC
and LTC homes, age was associated with an increased risk of
mortality, but this was not evident in the CCC sample. On the
other hand, being female was a protective factor in each setting,
but only slightly so in CCC. In all three settings, higher CHESS
scores were related to higher hazard ratios for mortality after
adjusting for age, sex and diagnosis. However, the various
neurological diagnoses were only weakly (and inconsistently)
related to mortality after adjusting for age, sex, and CHESS
score. Only ALS was consistently associated with an elevated
mortality risk, but Alzheimer’s and related dementias and
Parkinson’s were consistently negatively associated with mortality
in the adjusted models. The other diagnostic groups were either
not significantly different than the reference group or they had
inconsistent patterns across care settings. Table 5 provides the c
statistics (and 95% confidence limits) obtained from logistic
regression models for mortality as a binary outcome within a 6-
month period using the same independent variables as the survival
models in Table 4. In each care setting, the value of c was modest
(,0.70) for the baseline models with the 11 diagnostic variables,
age and sex; however, the addition of CHESS substantially
improved the performance of these models in all three care
settings.
Table 6 provides the number of deaths per 1,000 person years
by CHESS and care setting in order to describe the magnitude of
mortality for selected diagnoses in the study samples. As might be
expected, mortality tends to be lowest in home care settings and
highest in complex continuing care hospitals/units. When
mortality was considered within sectors, the number of deaths
per 1,000 person years was reasonably comparable within CHESS
levels across the diagnostic groups. The variations evident would
be explained, at least in part, by the lack of age and sex
adjustments for these rates.
Discussion
The present study provided strong evidence for the predictive
validity of the CHESS scale with regard to survival in a variety of
settings and populations. Higher CHESS scores were strong
predictors of mortality in home care, nursing home and complex
continuing care hospital settings. This trend was evident in the
overall population, among persons with neurological conditions as
a general category, and also within each of the 11 diagnoses
considered here. The only exceptions to these trends were likely
the result of reduced cell sizes for certain conditions. For example,
the small sample size for Huntington’s in HC and CCC may have
resulted in insufficient power for analyses of CHESS in those
settings.
There are a number of ways in which CHESS may prove useful
for clinical, administrative, policy-development, evaluation and
research purposes. Clearly, the present results suggest that CHESS
scores can provide meaningful clinical insights that would be
relevant to care planning and service delivery for persons with
neurological conditions. For example, CHESS can identify those
who may have reversible instability and who require immediate
attention (see, for example, the examination of CHESS in heart
failure patients [20]). It can also inform discussions related to
prognosis and it may be used as a severity measure to describe the
level of instability in the person’s health status. The intensity of
services offered or the frequency of monitoring or reassessment
may be guided, at least in part, based on these scores.
Administrative and policy related applications may include the
use of CHESS in case mix systems for predicting resource intensity
or as a consideration in eligibility systems or targeting criteria for
services involving different levels of clinical expertise. An
important benefit of the CHESS distribution is that the
populations of greatest concern, those with higher CHESS scores,
are a relatively small group. Therefore using CHESS for eligibility
or targeting criteria produces a manageable number of individuals
to focus on for intensive services and advanced care planning.
Research and evaluation studies on clinical outcomes related to
neurological conditions could reasonably use CHESS as a
covariate to adjust for differences in medical complexity or health
instability. This would be important for any performance
measurement initiatives that would aim to evaluate the quality
of care for persons with the conditions considered here.
Most of the associations of neurological conditions with
mortality were modest compared to those for age and CHESS.
In part this may be because the reference group for each
neurological condition (coded as a series of binary variables) likely
included other neurological conditions and serious non-neurolog-
ical conditions (e.g., heart failure, cancer). Also, the notable
heterogeneity of sociodemographic and clinical characteristic
between neurological diagnoses and across care settings clearly
points to the need for information beyond diagnosis alone when
considering vulnerable populations across the continuum of care.
Indeed, the results presented here suggest that these other
covariates that deal with underlying frailty are considerably more
important than diagnosis alone when examining trends in
mortality in HC, LTC and CCC settings. In addition to CHESS
scores, clinical variables that could be considered include gait
speed and impairments in activities of daily living, both of which
have been shown to predict mortality in older persons [9,30].
Although there have been some algorithms developed to predict
mortality in specific diagnostic groups, the CHESS scale has a
number of advantages over more specialized solutions reported
elsewhere. First, the CHESS score is embedded within most of the
instruments within the interRAI suite of assessments. Hence, any
jurisdiction that implements these instruments for their various
applications, including care planning, quality monitoring, outcome
measurement and resource allocation will by default have CHESS
scores available for all persons assessed with these instruments with
no additional cost in staff time. The broad national and
international use of the interRAI instruments will therefore also
permit cross-jurisdictional comparisons of the experiences of
person with neurological conditions after adjusting for factors like
CHESS scores. The ability to use CHESS as a generic algorithm
to predict survival is also a distinct advantage over disease-specific
solutions because this allows for direct comparisons across
diagnostic groups. Moreover, many disease-specific algorithms
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include items that are a function of the health system (e.g.,
diagnostic delay) rather than clinical characteristics of the person
making their cross-national utility limited.
The CHESS score should also be considered to be a dynamic
clinical measure. Unlike static measures such as the age of onset of
symptoms, the items that comprise the CHESS score (e.g.,
shortness of breath) may be modifiable. Future research should
examine the use of CHESS as a time dependent covariate to
determine the impact of changes in CHESS score over time.
The cross-sector differences in the associations of various risk
factors with mortality may reflect, at least in part, differences in the
reference populations against whom persons with neurological
conditions are compared. For example, ALS has an adjusted
hazard ratio of 1.97 in home care, but less than 1.20 in complex
continuing care and nursing homes. In those latter two settings,
there is a more uniformly high rate of impairment in all service
recipients, whereas there is a greater degree of variation between
the least and the most impaired persons in home care. For
example, the sample descriptions in Table 1 showed that persons
with ALS in Home Care had an almost six times higher
percentage of individuals with moderate or worse ADL impair-
ment compared with the non-neurological population. The
corresponding ratios in CCC hospitals/units and nursing homes
were 1.4 and 1.5, respectively. Hence, diagnosis appears less useful
as a predictor of mortality in more intensive care settings, but
CHESS appears to perform consistently well irrespective of care
setting.
The present study also demonstrates the diversity of persons
with neurological conditions. There are marked differences in the
mortality experience, demographic and clinical characteristics
between diagnostic groups indicating that they should not be
considered to represent a collectively homogeneous population.
However, it is also clear that there are notable differences in the
mortality experience of persons with the same neurological
diagnosis within and between care settings. This diversity within
diagnosis points to the need for comprehensive assessment as a
basis for care planning and service provision.
The fact that CHESS is not a biological based marker may be a
limitation given that it relies on subjective clinical appraisals for at
least some scale component rather than more objective physio-
logical measures. Several studies have examined the inter-rater
reliability for these measures, and they consistently meet standards
for acceptable levels of agreement [23,25]. However, these
instruments do depend on good training, effective communication,
and appropriate clinical skills to evaluate the person’s health status.
It should be regarded as a strength that interRAI assessments can
be used to inform clinical practice (i.e., care planning and person
level outcome measurement) and management decisions (e.g.,
quality indicators, case mix classification), because the counter-
vailing incentives for these different applications would tend to
balance each other out. On the other hand, if the assessment were
used only for a single application (e.g., funding) one might expect
that clinical measures like CHESS would become less effective as
predictors of health outcomes in these settings. Therefore, it is
essential to put in place mechanisms to ensure the quality of data
gathered as part of the routine assessment process.
Conclusions
The CHESS scale provides a useful indicator of mortality risk
for persons with neurological conditions in different health service
settings across the continuum of care. It differentiates mortality
risk within the overall population, those with neurological
conditions and specific neurological subgroups. CHESS provides
valuable information that clinicians, service providers, policy
makers and researchers can use to inform decisions related to the
care of persons with neurological conditions.
Acknowledgments
This study is part of the National Population Health Study of Neurological
Conditions. We wish to acknowledge the membership of Neurological
Health Charities Canada and the Public Health Agency of Canada for
their contribution to the success of this initiative. The opinions expressed in
this publication are those of the authors/researchers, and do not
necessarily reflect the official views of the Public Health Agency of Canada.
Author Contributions
Conceived and designed the experiments: JPH JWP. Analyzed the data:
JPH JWP. Wrote the paper: JPH. Drafted the initial version of the paper:
JPH. Contributed to the revision of the document and provided final
approval: JPH JWP LM LK GH.
References
1. World Health Organization (2007) Global burden of neurological disorders –
estimates and projections. Neurological Disorders: Public Health Challenges,
Geneva: World Health Organization. pp. 27–39.
2. Pritchard C, Mayers A, Baldwin D (2013) Changing patterns of neurological
mortality in the 10 major developed countries – 1979–2010. Public Health 127:
357–368.
3. Czira ME, Baune BT, Roesler A, Pfadenhauer K, Trenkwalder C, et al. (2014)
Association between neurological disorders, functioning and mortality in the
elderly. Acta Neurol Scand 129: 1–9.
4. Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu F, et al. (2012) Relative
mortality and survival in multiple sclerosis: Findings from British Columbia,
Canada. J Neurol Neurosurg Psychiatry 83: 61–66.
5. Kaufmann P, Levy G, Thompson JLP, DelBene ML, Battista V, et al. (2005)
The ALSFRSr predicts survival time in an ALS clinic population. Neurology 64:
38–43.
6. Scotton WJ, Scott KM, Moore DH, Almedom L, Wijesekera LH, et al. (2012)
Prognostic categories for amyotrophic lateral sclerosis. Amyotroph Lateral Scler
13: 502–508.
7. Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G (2010) What predicts
mortality in Parkinson’s Disease? A prospective population-based long-term
study. Neurology 75: 1270–1276.
8. Steyerberg EW, Mushkudiani N, Perel P, Butcher I, Lu J (2008) Predicting
outcome after traumatic brain injury: Development and international validation
of prognostic scores based on admission characteristics, PLoS Med 5: 1251–
1261.
9. Hirdes JP, Frijters DH, Teare GF (2003) The MDS-CHESS scale: a new
measure to predict mortality in institutionalized older people. J Am Geriatr Soc
51: 96–100.
10. Mor V, Intrator O, Unruh MA, Cai S (2011) Temporal and geographic
variation in the validity and internal consistency of the nursing home Resident
Assessment Minimum Data Set 2.0. BMC Health Serv Res 11: 78.
11. Hjaltado´ttir I, Hallberg IR, Ekwall AK, Nyberg P (2011) Predicting mortality of
residents at admission to nursing home: a longitudinal cohort study. BMC
Health Serv Res 11: 86.
12. Lee JS, Chau PP, Hui E, Chan F, Woo J (2009) Survival prediction in nursing
home residents using the Minimum Data Set subscales: ADL Self-Performance
Hierarchy, Cognitive Performance and the Changes in Health, End-stage
disease and Symptoms and Signs scales. Eur J Public Health19: 308–312.
13. Armstrong JJ, Stolee P, Hirdes JP, Poss JW (2010) Examining three frailty
conceptualizations in their ability to predict negative outcomes for home-care
clients. Age Ageing 39: 755–758.
14. Hirdes JP, Freeman S, Smith TF, Stolee P (2012) Predictors of caregiver distress
among palliative home care clients in Ontario: evidence based on the interRAI
Palliative Care. Palliat Support Care 10: 155–163.
15. Lutomski JE, Baars MAE, Buurman BM, den Elzen WPJ, Jansen APD, et al.
(2013) Validation of a Frailty Index from the Older Persons and Informal
Caregivers Survey Minimum Data Set. J Am Geriatr Soc 61: 1625–1627.
16. Rockwood K, Mitnitski A (2011) Frailty defined by deficit accumulation and
geriatric medicine defined by frailty. Clin Geriatr Med 27: 17–26.
17. Mitnitski AB, Mogilner AJ, MacKnight C, Rockwood K (2002) The mortality
rate as a function of accumulated deficits in a frailty index. Mech Ageing Dev
123: 1457–1460.
interRAI CHESS Scale and Mortality
PLOS ONE | www.plosone.org 12 June 2014 | Volume 9 | Issue 6 | e99066
18. Hirdes JP (2006) Addressing the health needs of frail elderly people: Ontario’s
experience with an integrated health information system. Age Ageing 35: 329–
331.
19. Carpenter GI, Hirdes JP (2013) Using interRAI assessment systems to measure
and maintain quality of long-term care in OECD/European Commission A
Good Life in Old Age? Monitoring and Improving Quality in Long-term Care,
OECD Health Policy Studies, OECD Publishing 93–139.
20. Tjam EY, Heckman GA, Smith S, Arai B, Hirdes J, et al. (2012) Predicting heart
failure mortality in frail seniors: Comparing the NYHA functional classification
with the Resident Assessment Instrument (RAI) 2.0. Int J Cardiol 155: 75–80.
21. Bernabei R, Gray L, Hirdes J, Pei X, Henrard J-C, et al. (2009). International
Gerontology in Hazzard’s Geriatric Medicine and Gerontology 6th Edition,
Halter JB, Ouslander JG, Tinetti ME, Studenski S, High KP, Asthana S (Eds),
New York: McGraw Medical 69–96.
22. Caesar-Chavannes CR, MacDonald S (2013) National Population Health Study
of Neurological Conditions in Canada. Chronic Dis Inj Can33: 188–191.
23. Hirdes JP, Ljunggren G, Morris JN, Frijters DH, Finne Soveri H, et al. (2008)
Reliability of the interRAI suite of assessment instruments: a 12-country study of
an integrated health information system. BMC Health Serv Res 8: 277.
24. Gray LC, Berg K, Fries BE, Henrard JC, Hirdes JP, et al. (2009) Sharing clinical
information across care settings: the birth of an integrated assessment system.
BMC Health Serv Res 9: 71.
25. Poss JW, Jutan NM, Hirdes JP, Fries BE, Morris JN, et al. (2008) A review of
evidence on the reliability and validity of Minimum Data Set data. Healthc
Manage Forum 21: 33–39.
26. Landi F, Tua E, Onder G, Carrara B, Sgadari A, et al. (2000) Rinaldi C,
Gambassi G, Lattanzio F, Bernabei R; SILVERNET-HC Study Group of
Bergamo. Minimum data set for home care: a valid instrument to assess frail
older people living in the community. Med Care 38: 1184–1190.
27. Hirdes JP, Poss JW, Caldarelli H, Fries BE, Morris JN, et al. (2013) An
evaluation of data quality in Canada’s Continuing Care Reporting System
(CCRS): secondary analyses of Ontario data submitted between 1996 and 2011.
BMC Med Inform Decis Mak 13: 27.
28. Foebel AD, Hirdes JP, Heckman GA, Kergoat MJ, Patten S, et al. (2013)
Diagnostic data for neurological conditions in interRAI assessments in home
care, nursing home and mental health care settings: a validity study. BMC
Health Serv Res 13: 457.
29. Gambassi G, Landi F, Peng L, Brostrup-Jensen C, Calore K, et al. (1998)
Validity of diagnostic and drug data in standardized nursing home resident
assessments: potential for geriatric pharmacoepidemiology. SAGE Study Group.
Systematic Assessment of Geriatric drug use via Epidemiology. Med Care 36:
167–179.
30. Sabia S, Dumurgier J, Tavernier B, Head J, Tzourio C, et al. (2014). Change in
fast walking speed preceding death: Results from a prospective longitudinal
cohort study. J Gerontol A Biol Sci Med Sci 69: 354–356.
interRAI CHESS Scale and Mortality
PLOS ONE | www.plosone.org 13 June 2014 | Volume 9 | Issue 6 | e99066
